After the the recent failure of Eli Lilly’s experimental anti-amyloid therapy solanezumab (read the article ),  Eli Lilly  and AstraZeneca last week unveiled a global agreement to jointly develop the investigational selective amyloid-beta 42 antibody MEDI1814, which is currently in Phase I trials for the treatment of Alzheimer’s disease.

According to the companies, amyloid-beta 42 is “a form of amyloid-beta that is particularly associated” with Alzheimer’s disease, and that “binding dose-dependently reduces levels of this peptide, potentially slowing the progression.” Under the terms of the agreement, Eli Lilly will make an upfront payment of $30 million to AstraZeneca, which the US drugmaker plans to record as a charge in the current quarter. Other financial terms of the agreement were not divulged.

• Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer’s Disease – (Eli Lilly)
• Astrazeneca and Lilly to develop second potentially disease-modifying treatment for Alzheimer’s disease – (AstraZeneca)

Read futher on Alzheimer:

Financial Times 12/14/2016 Early intervention is key to tackling Alzheimer’s

Finalcial Timese 11/26/2016 – The case for prioritising Alzheimer’s research

Finalcial Timese 11/26/2016 – Eli Lilly shares drop